None listed
Conditions
Interventions
Dietary Supplement : • SGF500 group: 1 times a day, 1 capsule once, before breakfast for 12 weeks{350 mg/day (Bacillus amyloliquefaciens spore: 1 x 10^9 CFU/day, GF101 500 U/day)}
• Placebo group: 1
Sponsors
Jeonbuk National University Hospital
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1) OSDI =13 at screening test 2) TBUT=10 or (+) on Fluorescein staining at screening test 3) Participants who have fully understand the information provided about the study voluntarily decided to participate and agree to comply with precautions
Exclusion criteria
Exclusion criteria: 1) Patients with a clinically significant disease requiring treatment (i.e., cardiovascular system, endocrine system, immune system, respiratory system, hepatobiliary system, kidney and urinary system, neuropsychiatric system, musculoskeletal inflammation, inflammatory disease, blood and tumor disease, gastrointestinal disease, etc.) 2) Patients with a history of antipsychotic medication use within 3 months prior to the screening examination 3)Patients who have participated in other clinical trials within 3 months prior to the screening examination 4)Patients who are judged ineligible to participate in the trial by the principal investigator for other reasons, including laboratory test outcomes
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Ocular Surface Disease Index;tear break-up time | — |
Secondary
| Measure | Time frame |
|---|---|
| Visual analog scale;Schirmer’s test;Meibomian gland test;Fluorescein staining;inflammatory outcome;antioxidant outcome | — |
Countries
Korea, Republic of
Contacts
Public ContactIn Cheon You
Jeonbuk National University Hospital
Outcome results
None listed